Treating donor tissue with a special cocktail of molecules improves outcomes and promotes survival of high-risk corneal transplants
Boston, Mass. — Treating donor corneas with a cocktail of molecules prior to transplanting to a host may improve survival of grafts and, thus, outcomes in high-risk corneal transplant patients, according to a new study led by researchers at Massachusetts Eye and Ear. The findings,
Findings may lead to the development of therapies to prevent damage to the retina, the light-sensitive tissue at the back of the eye.
Boston, Mass. — Chemical eye burns caused by alkali agents not only injure the front of the eye — the cornea, where the contact takes place — but also cause widespread damage to the light-sensitive tissue at the back of the eye (the retina) as well, often leading to optic nerve damage and glaucoma. In a report
Boston, Mass. — The brains of those who are born blind make new connections in the absence of visual information, resulting in enhanced, compensatory abilities such as a heightened sense of hearing, smell and touch, as well as cognitive functions (such as memory and language) according to a new study led by Massachusetts Eye and Ear researchers. The report, published online today
From May 1st to May 5th, more than 11,000 people attended the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, WA. Eye and vision researchers from more than 75 countries presented their current research, discussed emerging technologies, and strategized ways to overcome the current challenges facing ophthalmology and vision science. Harvard Ophthalmology was well-represented at the meeting, and faculty and trainees contributed 247 posters and presentations this year.
ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has announced that Joan W. Miller, MD, Chair of the Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, is one of five of the world’s premier retinal disease thought leaders who will serve on its newly formed scientific advisory board (SAB). The goal of
On October 7th and 8th, Jason Comander, MD, PhD, andLeo Kim, MD, PhD, participated in the Alliance for Eye and Vision Research (AEVR) Emerging Vision Scientists Program. This program allows scientists to meet with members of Congress to discuss the importance of vision research in the continuing fight to prevent blindness.